知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

1115 records (took 0.026 seconds)

    Anti-TOSO chimeric antigen receptor and its use
    74.
    发明申请
    Anti-TOSO chimeric antigen receptor and its use 有权
    抗TOSO嵌合抗原受体及其用途

    公开(公告)号：US20160347854A1

    公开(公告)日：2016-12-01

    申请号：US15166306

    申请日：2016-05-27

    Applicant: Universitaet zu Koeln

    Inventor： Andreas HOMBACH ,  Elena FAITSCHUK ,  Hinrich ABKEN

    IPC: C07K16/30 ,  C07K14/705 ,  C07K14/725 ,  A61K35/17

    CPC classification number: C07K16/30 ,  A61K35/17 ,  A61K48/00 ,  A61K48/005 ,  A61K2035/124 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  C12N5/00 ,  C12N2740/10043

    Abstract: In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.

    Abstract translation: 在第一方面，本发明涉及在有需要的受试者中用于治疗T细胞白血病/淋巴瘤TOSO +癌的过继性细胞治疗方法中具有嵌合抗原受体（CAR）的遗传修饰的T细胞。 特别地，本发明涉及含有并表达特异性嵌合抗原受体的遗传工程化T细胞，其对TOSO +癌细胞有毒性，而对TOSO +非癌细胞毒性较小或无毒性，特别是无毒性 到正常的B细胞及其前体。 在另一方面，本发明涉及具体的嵌合抗原受体和编码该嵌合抗原受体的核酸分子以及含有该嵌合抗原受体的载体和细胞。

    RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF
    79.
    发明申请
    RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF 审中-公开
    受体指导结构及其用途

    公开(公告)号：US20160331840A1

    公开(公告)日：2016-11-17

    申请号：US15112162

    申请日：2015-01-16

    Applicant: CEDARS-SINAI MEDICAL CENTER

    Inventor： Lali K. MEDINA-KAUWE

    IPC: A61K47/48 ,  A61K31/7105

    CPC classification number: A61K47/48246 ,  A61K9/0019 ,  A61K9/5169 ,  A61K31/7105 ,  A61K47/64 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6929 ,  C07K14/005 ,  C07K2319/55 ,  C07K2319/74

    Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.

    Abstract translation: 本文公开了包含靶向细胞表面分子的配体的药物递送分子; 膜渗透结构域; 和有效载荷绑定域; 和包含其的药物组合物。 还公开了治疗癌症的方法，抑制癌症进展，预防癌症转移以及在有需要的受试者中向治疗化合物递送治疗化合物，所述方法包括鉴定有需要的受试者; 提供包含本文公开的药物递送分子的组合物; 并向受试者施用有效量的组合物。

    METHOD OF MANUFACTURING A LYSIN PROTEIN CAPABLE OF DIRECTLY LYSING ACINETOBACTER BAUMANNII
    80.
    发明申请
    METHOD OF MANUFACTURING A LYSIN PROTEIN CAPABLE OF DIRECTLY LYSING ACINETOBACTER BAUMANNII 审中-公开
    一种能直接诱导乙酰胆碱酯酶的蛋白质蛋白质的制备方法

    公开(公告)号：US20160312203A1

    公开(公告)日：2016-10-27

    申请号：US15203638

    申请日：2016-07-06

    Applicant: I-SHOU UNIVERSITY

    Inventor： Chih-Hsin Hung ,  Huei-Ru Luo ,  Jen-Yi Wang

    IPC: C12N9/36

    CPC classification number: C12N9/2462 ,  C07K2319/00 ,  C07K2319/74 ,  C12N9/88 ,  C12N2795/00022 ,  C12Y302/01017 ,  C12Y402/02002

    Abstract: The invention discloses a method of manufacturing a lysin protein capable of directly lysing Acinetobacter baumannii without pretreatment processing using chloroform or EDTA, comprising: transforming an expression plasmid into E. coli, wherein the expression plasmid is deposited at DSMA-Deutsche Sammlung von Mikroorganismen and Zellkulturen with deposit number DSM32023; expressing the expressing plasmid by the E. coli to form lysin protein having an amino acid sequence as set forth in SEQ ID NO: 6; lysing the E. coli containing the lysing protein to obtain a supernatant by centrifugating the E. coli lysate; mixing the supernatant and Ni2+ resins, washing the unbound protein by a binding buffer containing 50 mM Tris-HCl (pH 8.2), 15 mM MgCl2, 20% (v/v) glycerol, 0.05% β-ME and 0.1 mM PMSF; and eluting the purified lysing protein by an elution buffer containing 50 mM Tris-HCl (pH 8.2), 15 mM MgCl2, 20% (v/v) glycerol, 0.05% β-ME, 0.1 mM PMSF and 250 mM imidazole.

    Abstract translation: 本发明公开了一种能够直接溶解鲍氏不动杆菌而不用氯仿或EDTA进行预处理的赖氨酸蛋白质的制造方法，其特征在于：将表达质粒转化到大肠杆菌中，其中所述表达质粒沉积在DSMA-Deutsche Sammlung von Mikroorganismen和Zellkulturen 存款编号DSM32023; 用大肠杆菌表达表达质粒以形成具有SEQ ID NO：6所示氨基酸序列的赖氨酸蛋白; 裂解含有裂解蛋白的大肠杆菌，通过离心大肠杆菌裂解液得到上清液; 混合上清液和Ni2 +树脂，通过含有50mM Tris-HCl（pH 8.2），15mM MgCl 2，20％（v / v）甘油，0.05％β-ME和0.1mM PMSF的结合缓冲液洗涤未结合的蛋白质; 并通过含有50mM Tris-HCl（pH 8.2），15mM MgCl 2，20％（v / v）甘油，0.05％β-ME，0.1mM PMSF和250mM咪唑的洗脱缓冲液洗脱纯化的裂解蛋白。

Patent Agency Ranking